Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

[1] Haura EB(1995)Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trails BMJ 311 899-909

[2] Rowinsky EK(2001)Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies Cancer Control 8 326-336

[3] Rusch V(2000)The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents Drugs 60 1-14

[4] Klimstra D(1997)Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression Clin Cancer Res 3 515-522

[5] Venkatraman E(1993)Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Res 53 2379-2385

[6] Pisters PW(1986)Expression of epidermal growth factor receptor (EGF-R) in human lung tumours Br J Cancer 54 265-269

[7] Langenfeld J(2003)Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors Ann Oncol 14 922-930

[8] Dmitrovsky E(2003)Severe acute interstitial pneumonia and gefitinib Lancet 361 137-139

[9] Rusch V(2003)FDA drug approval summary: gefitinib (ZD1839) (Iressa Oncologist 8 303-306

[10] Baselga J(2003)) tablets J Clin Oncol 21 2237-2246

[1] Haura EB(1995)Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trails BMJ 311 899-909

[2] Rowinsky EK(2001)Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies Cancer Control 8 326-336

[3] Rusch V(2000)The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents Drugs 60 1-14

[4] Klimstra D(1997)Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression Clin Cancer Res 3 515-522

[5] Venkatraman E(1993)Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Res 53 2379-2385

[6] Pisters PW(1986)Expression of epidermal growth factor receptor (EGF-R) in human lung tumours Br J Cancer 54 265-269

[7] Langenfeld J(2003)Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors Ann Oncol 14 922-930

[8] Dmitrovsky E(2003)Severe acute interstitial pneumonia and gefitinib Lancet 361 137-139

[9] Rusch V(2003)FDA drug approval summary: gefitinib (ZD1839) (Iressa Oncologist 8 303-306

[10] Baselga J(2003)) tablets J Clin Oncol 21 2237-2246